Thymic Carcinoma
Conditions
Keywords
Thymic malignancy, Thymic Carcinoma
Brief summary
This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit and/or PDGF. If this current trial is positive, it opens the door to evaluate other combination of drugs with imatinib in thymic tumors.
Detailed description
Thymic carcinomas are particularly more concerning due to their aggressive metastatic nature and shorter overall survival, in comparison to their lesser-malignant thymoma counterparts. This necessitates the need for systemic therapy. Due to the paucity of thymic carcinoma cases, the ideal regimen for locally advanced or metastatic thymic carcinomas is not defined.To this point, there has not been a study using imatinib in thymic tumors expressing the KIT tyrosine kinase protein or PDGF tyrosine kinase protein. This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit and/or PDGF. If this current trial is positive, it opens the door to evaluate other combination of drugs with imatinib in thymic tumors.
Interventions
DRUGGleevec (imatinib)
Imatinib 600mg po qd X 21 days.
Sponsors
Indiana University School of Medicine
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological or cytological proof of advanced C-KIT positive or PDGFR positive thymic carcinoma. For protocol purposes, advanced disease is defined as disease * Patient must have at least one documented measurable lesion obtained by imaging within 28 days prior to being registered for protocol therapy. * No prior imatinib therapy. * Age \> 18 years at the time of consent * ECOG performance status of 0 or 1 * ANC ≥ 1500/mm3,Platelet count ≥ 100,000/mm,Total bilirubin \< 1.5ULN,3.10 Serum creatinine ≤ 1.7 mg/dl,ALT and AST ≤ 3 x ULN
Exclusion criteria
* Clinically significant infections as judged by the treating investigator * Clinically significant concurrent illnesses * Females of childbearing potential not using birth control or breastfeeding * Prior radiation therapy \> 25% of the bone marrow * Symptomatic brain metastasis * History of Grade III/IV cardiac problems * History of major surgery within 14 days prior to being registered * Treatment with any investigational agent within 30 days prior to being registered for protocol therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the objective response rate of imatinib in patients with c-kit or PDGF positive thymic carcinoma. | baseline through progression |
| To determine the duration of remission of patients with thymic carcinoma treated with imatinib. | baseline through progression |
| To determine the toxicity of imatinib in this patient population. | baseline through end of study |
| To determine the incidence of kit mutations in thymic malignancies. | baseline |
Countries
United States
Outcome results
None listed